Companies
Dexcom
American companies like Abbott and Dexcom control the vast majority of the global CGM market with devices like FreeStyle Libre 3 and Dexcom G7.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | Capacity to produce millions of sensors annually at Ireland and Malaysia facilities | investpenang.gov.my · businesswire.com |
| Certification | G7 earned CE Mark in March 2022 | content.edgar-online.com · s201.q4cdn.com |
| Regulatory approval | FDA marketing authorization for G7 (December 2022) and 15-day G7 (April 2025); Stelo OTC clearance (March 2024) | content.edgar-online.com · s201.q4cdn.com · marketsandmarkets.com |
| Production site | Manufacturing facilities in Mesa, Arizona; Penang, Malaysia; and Athenry, Ireland | investpenang.gov.my · s201.q4cdn.com · drugdeliverybusiness.com · sandiegouniontribune.com |
| Revenue | $4.66 billion in 2025; $1.31 billion in Q2 2026 | investors.dexcom.com · s201.q4cdn.com · sec.gov |
Independent sources: businesswire.com · content.edgar-online.com · drugdeliverybusiness.com · investpenang.gov.my · marketsandmarkets.com · s201.q4cdn.com · sandiegouniontribune.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Wearable biodiagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.